Israeli drug delivery specialist UroGen picked up a development deal with Allergan to help the pharma deliver drugs to the urinary bladder. UroGen gets $17.5 million right away in the deal, as well as milestones down the road, according to a report from Israel’s Globes.
Generics of Johnson & Johnson’s ADHD pill Concerta are hitting hard times due to an FDA crackdown on their bioequivalence. The agency said six months ago that generics makers Lannett and Mallinckrodt had that much time to confirm their extended-release technology matched that of J&J’s.
Researchers at two U.S. universities have developed a method by which genetic diseases in utero can be treated via an injection into the surrounding fluid. They designed specific genetic sequences to alter the aberrant gene expressions in the fetus.
French pharma Nicox, which specializes in ophthalmic R&D, has been issued a complete response letter from the FDA regarding its cetirizine eye drops after an inspection at a facility that produces the main ingredient.
Cornell Professor Ulrich Wiesner’s C-dots are showing more and more that they could be the next big step in nanotech drug delivery. In their latest incarnation, the diagnostic and delivery combination particles have shown that they can alone deprive cancer cells of nutrients, resulting in their death.
Researchers at the Polytechnique Montreal NanoRobotics Laboratory have found that bacteria imbued with magnetic capabilities can be a way to deliver targeted loads of chemotherapy to tumors with fewer side effects.
Northern Irish nanotechnology specialist SiSaf pulled in a first round of funding worth $3.5 million. The players investing in the company are Vickers Venture Partners, Exen Capital and Invest Northern Ireland.